Understanding the problem of inadequately staging early ovarian cancer

Autor: J. B. M. Z. Trimbos, Corneel Coens, Ignace Vergote, Ailko Zwinderman, Petra Timmers

Publikováno v: European journal of cancer (Oxford, England, 46(5), 880-884. Elsevier Limited
European Journal of Cancer, 46(5), 880-884

Background: Early ovarian cancer patients are often incompletely staged during initial surgery.(1-3) This omission can have serious adverse consequences for the prognosis of patients as the completeness of surgical staging has been identified as an i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9eedf3222d7af2f63c9be90523f6e419
https://doi.org/10.1016/j.ejca.2009.12.012

Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial

Autor: Giovanna Scarfone, Corneel Coens, Massimo Franchi, Saverio Tateo, Livia Giurgea, Jan B. Vermorken, Caterina Madronal, Ignace Vergote, Constantino Mangioni, Gerardo Zanetta, Sergio Pecorelli, J. Baptist Trimbos, Giorgio Bolis, Petra Timmers

Publikováno v: Journal of the National Cancer Institute

Background: All randomized trials of adjuvant chemotherapy for early-stage ovarian cancer have lacked the statistical power to show a difference in the effect on survival between adjuvant chemotherapy and no adjuvant chemotherapy. They have also not

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::349c374ff89c3d6305fd87d9689f8913
https://doi.org/10.1093/jnci/95.2.113

Genomic aberrations relate early and advanced stage ovarian cancer

Autor: P. M. J. J. Berns, Isabelle Cadron, Jan H.W. Veerbeek, Oscar Krijgsman, J. Baptist Trimbos, Jurgen M.J. Piek, Afra Zaal, Gerrit A. Meijer, Ignace Vergote, Maria E. L. van der Burg, Wessel N. van Wieringen, René H.M. Verheijen, Wouter J. Peyrot, Paul J. van Diest, Ronald P. Zweemer, Bauke Ylstra, Petra Timmers

Publikováno v: Cellular Oncology, 35(3), 181-188. IOS Press
Cellular Oncology, 35(3), 181-188
Zaal, A, Peyrot, W J, Berns, P M J J, van der Burg, M E L, Veerbeek, J H W, Trimbos, J B, Cadron, I, van Diest, P J, van Wieringen, W N, Krijgsman, O, Meijer, G A, Piek, J M J, Timmers, P J, Vergote, I, Verheijen, R H, Ylstra, B & Zweemer, R P 2012, ' Genomic aberrations relate early and advanced stage ovarian cancer ', Cellular Oncology, vol. 35, no. 3, pp. 181-188 . https://doi.org/10.1007/s13402-012-0077-5
Cellular Oncology (Dordrecht)

Background Because of the distinct clinical presentation of early and advanced stage ovarian cancer, we aim to clarify whether these disease entities are solely separated by time of diagnosis or whether they arise from distinct molecular events. Meth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19ed5c2dc9446f1bf4724f695a5a8a35
https://research.vu.nl/en/publications/e1bfadc3-84d0-4e3d-b7f0-8d5a65d40861

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide

Autor: Jim Cassidy, Benoit Baron, Gavin Stuart, Elizabeth Eisenhauer, Gavin Shreeves, A. E. Nelstrop, Martine Piccart, Petra Timmers, Gordon J. S. Rustin, Soeren M. Bentzen, Kamma Bertelsen

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(1)

Purpose A definition for progression of ovarian cancer has been proposed based on either a confirmed doubling of CA-125 levels from the upper limit of normal or from the nadir level if levels are persistently elevated. Retrospectively, we determined

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b82e63faffcb6acea9fcdb9be803aaf7
https://pubmed.ncbi.nlm.nih.gov/16382112